Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.

    Intercept Starts OCA Trial for NASH Patients With Cirrhosis

    Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.

      Shire (SHPG) to Report Q4 Earnings: What's in the Cards?

      Shire (SHPG) will report its Q4 results on Feb 14, 2018.

        Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?

        Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.

          Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?

          The recent weakness in lead drug Ocaliva sales due to safety issues may mar Intercept's (ICPT) performance in the fourth quarter.

            FDA Okays J&J's Prostate Cancer Drug in First-Line Setting

            The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.

              Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

              Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.

                Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates

                Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.

                  Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?

                  Zoetis (ZTS) is working on returning value to shareholders in the form of share buybacks and dividends.

                    Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?

                    Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.

                      Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow

                      Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.

                        Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

                        Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

                          Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4

                          Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.

                            Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

                            Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

                              Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural

                              Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural

                                5 Biotech Stocks Set to Trump Estimates This Earnings Season

                                Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.

                                  Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study

                                  Bristol-Myers' (BMY) blockbuster drug, Opdivo, in combination with Yervoy, proves its worth again by demonstrating superiority in a lung cancer study.

                                    Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study

                                    Spectrum Pharmaceuticals' (SPPI) Rolontis meets primary endpoint in a phase III study for management of neutropenia in early stage breast cancer.

                                      Pfizer Files for Xtandi in Early Stage Prostate Cancer

                                      Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

                                        Roche Reports Positive Data From Tecentriq-Avastin Study

                                        Roche reported positive results from a phase III study on the combination of immunotherapy drug Tecentriq and oncology drug Avastin.

                                          Tirthankar Chakraborty headshot

                                          5 of the Best Efficient Stocks for Your Portfolio

                                          Companies with a favorable efficiency level are expected to provide impressive returns as efficiency is believed to be positively correlated with price performance.

                                            Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?

                                            ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.

                                              Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?

                                              Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.

                                                Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                                                Alexion's (ALXN) Q4 results are likely to driven by Soliris' performance.

                                                  Strength Seen in Alkermes (ALKS): Stock Soars 8.7%

                                                  Alkermes (ALKS) was a big mover last session, as the company saw its shares rise more than 8% on Friday amid huge volumes.